REVERSIBLE NUKLEOTIDE ÄNDERUNG

European patent · EP4028407 · In force

Register entry

Publication number
EP4028407
Application number
EP20776287
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 10, 2020
Published
Jul 20, 2022
Granted
Aug 16, 2023
Protection ends at the latest
Sep 9, 2040
Next annual fee due
Sep 30, 2027
IPC classes
C07H 19/00 (2006.01)
C07H 21/00 (2006.01)
C07H 1/00 (2006.01)
C07H 19/10 (2006.01)
C07H 19/20 (2006.01)
Priority
US 201962898152 P 10.09.2019
PCT application
PCT/US2020/050126 10.09.2020
PCT publication
WO2021/050681 18.03.2021
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. Oct 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.09.2025 → 30.09.2026

    Published in Swissreg on 01.10.2025

  3. Oct 3, 2024

    Change

    Published in Swissreg on 03.10.2024

  4. Jun 26, 2024

    Change

    Published in Swissreg on 26.06.2024

  5. Oct 2, 2023

    Change

    Published in Swissreg on 02.10.2023

  6. Sep 6, 2023

    Agent entered

    Representative
    MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex

    Published in Swissreg on 06.09.2023

  7. Aug 16, 2023

    Granted

    Published in Swissreg on 16.08.2023

Parties

Holder

Pacific Biosciences of California, Inc.

1305 O'Brien Drive, Menlo Park, CA 94025, US

Agent

MICHELI & CIE SA

122, rue de Genève, CP 61, 1226 Thônex

Inventor

MALYSHEV, Denis

San Diego, CA 92121, US

FELDMAN, Aaron, W.

San Diego, CA 92121, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.